Article Text

Download PDFPDF
Use of antisecretory agents as a trial of therapy
  1. M B Fennerty
  1. Correspondence to:
    Dr M B Fennerty, Division of Gastroenterology, OHSU, PV-310, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201-3098, USA;


Dyspepsia is a common clinical condition, and its diagnostic evaluation and treatment result in the expenditure of enormous healthcare resources each year. Studies indicate that the omeprazole test is the most sensitive and cost effective test for diagnosing gastro-oesophageal reflux disease (GORD) in patients with extra-oesophageal or more “classic” symptoms suggestive of GORD. Studies also indicate that a therapeutic trial of omeprazole in patients with dyspepsia results in greater symptom improvement and lower costs than treatment with less potent acid suppression.

  • dyspepsia
  • gastro-oesophageal reflux disease
  • H2 receptor antagonist
  • omeprazole
  • trial of therapy
  • GORD
  • gastro-oesophageal reflux disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has received sponsorship for travel and an honorarium from AstraZeneca.

Linked Articles